Trial
NCT04582864
Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Washington University School of Medicine
Collaborators
MacroGenics; National Cancer Institute (NCI)
Condition
Relapsed Acute Myeloid Leukemia
Intervention
Flotetuzumab
Why stopped
The sponsor is no longer supporting the drug
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-12-06